Ad5-nCoV vaccine clinical trials
Also written Ad5-nCoV.
How each study uses Ad5-nCoV vaccine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2020 (7)
| Year | Studies |
|---|---|
| 2020 | 7 |
| 2021 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 7
CanSino Biologics Inc. (5) · Jiangsu Province Centers for Disease Control and Prevention (3) · Fundación Huésped (2) · Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China (2) · NPO Petrovax (1)
Often tested with
Tested in the same studies.
ZF2001 COVID-19 vaccine (1)
Studies
Open first, then newest update. How each study uses Ad5-nCoV vaccine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- Phase IIB Study of Recombinant Novel Coronavirus VaccineCompletedPhase 2Fundación HuéspedNCT05293223Written as Ad5-nCovHow we know
- Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Ad5-nCoV) in Adults 18 Years of Age and Older, Living With HIVCompletedPhase 2Fundación HuéspedNCT05005156Written as Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV)How we know
- Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19CompletedPhase 3NPO PetrovaxNCT04540419Written as Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)How we know
- Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and AboveCompletedPhase 3CanSino Biologics Inc.NCT04526990Written as Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)How we know
- A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy AdultsCompletedPhase 1Institute of Biotechnology, Academy of Military Medical Sciences, PLA of ChinaNCT04552366Written as Ad5-nCoVHow we know
- A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector)CompletedPhase 2Institute of Biotechnology, Academy of Military Medical Sciences, PLA of ChinaNCT04341389Written as Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)How we know
- Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for InhalationCompletedPhase 1/2CanSino Biologics Inc.NCT04840992Written as Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)How we know
- A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)CompletedPhase 2CanSino Biologics Inc.NCT04566770Written as Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)How we know
- Study on Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) in Elderly AdultsCompletedPhase 4Jiangsu Province Centers for Disease Control and PreventionNCT04952727Written as Recombinant SARS-CoV-2 Ad5 vectored vaccineHow we know
- Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit VaccineCompletedPhase 4Jiangsu Province Centers for Disease Control and PreventionNCT04833101Written as recombinant Ad5 vectored COVID-19 vaccineHow we know
- Study on Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine (Ad5 Vector)CompletedPhase 4Jiangsu Province Centers for Disease Control and PreventionNCT04892459Written as Recombinant SARS-CoV-2 Ad5 vectored vaccineHow we know
- Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy AdultsCompletedPhase 1CanSino Biologics Inc.NCT04313127Written as Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)How we know
- Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in CanadaStatus unknownPhase 1/2CanSino Biologics Inc.NCT04398147Written as Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)How we know
Given beside what is tested · 1 — Ad5-nCoV vaccine is usual care or a partner of the new treatment
Codes
What other systems call Ad5-nCoV vaccine · ClinicalTrials.gg INT001303
- MeSH (NLM) C000706167Ad5-nCoV vaccineOne source NLM
- UNII (FDA) 5AHC3V2UQSAD5-NCOVConfirmed NLM, Wikidata
- Wikidata Q96695265Ad5-nCoVConfirmed NLM, Wikidata
- DrugBank DB15655One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000706167 | Ad5-nCoV vaccine | One source NLM |
| UNII (FDA) | 5AHC3V2UQS | AD5-NCOV | Confirmed NLM, Wikidata |
| Wikidata | Q96695265 | Ad5-nCoV | Confirmed NLM, Wikidata |
| DrugBank | DB15655 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.